Rationale: Cyclosporine A (CsA) is a potent immunosuppressive agent originally used to prevent rejection after organ transplantation but now more frequently used for treatment of refractory autoimmune diseases. It can induce adverse effects, such as nephrotoxicity, gastrointestinal reactions, and gingival hyperplasia whist myopathy with subacute muscular atrophy are rare.
Introduction
Cyclosporine A (CsA) is a potent immunosuppressive agent originally used to prevent rejection after organ transplantation but now more frequently used for treatment of refractory autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and refractory nephrotic syndrome. [1] It can inhibit the cell-mediated immune reaction, B cell activity, production of T cell-dependent antibodies, and production and release of lymphoid factors such as interleukin 2 at the cellular level. It can induce adverse effects, such as nephrotoxicity, gastrointestinal reactions, and gingival hyperplasia whist metabolic myopathy with subacute muscular atrophy are rare. Our study describes a rare case of CsA-induced myopathy initially presenting with subacute muscular atrophy. Informed written consent was obtained from the patient for publication of this case report and accompanying images.
Case report
A 55-year-old male patient without known chronic disease was admitted to our department with edema of the face and lower extremities, massive proteinuria and hypoproteinemia were found after admission. He was diagnosed with "nephrotic syndrome"and renal biopsy confirmed idiopathic membranous nephropathy. He was treated with cyclosporine A at 3 mg/kg/d and prednisone at 0.5 mg/kg.d. The patients was discharged from hospital after his serum CsA concentration met clinical standards, meanwhile, his CPK value was normal and symptomatic relief.
More than 20 days later, gradually developed lower limb weakness, which were progressively aggravated until he was unable to stand or walk 1 month later. The patient was admitted again. A physical examination shows muscle atrophy of both lower extremities, which was more severe in the right thigh muscle than the left (Fig. 1) , decreased muscular tension of the limbs was also observed (grade V muscular tension of upper limbs, grade II muscular tension of right lower limb and grade III muscular tension of left lower limb).
No abnormalities were found in myozyme spectrum, electrolytes, and thyroid function. Electromyography and nerve conduction tests showed myoelectric changes caused by myogenic damage. Thigh muscle MRI scan indicated:
1. muscle atrophy of the right thigh with edema of lateral femoral muscle, biceps femoris, and semimembranosus 2. swelling of bilateral external obturator and pectineus muscles, effusion in the intermuscular septum.
Histological examination of muscle (quadriceps femoris) biopsy samples revealed the muscle fibers were obviously different in size and atrophic fibers distributed in small clusters or foci among normal fibers (as shown by Fig. 2a) . No broken red fibers and rimmed vacuoles were found (as shown by Fig. 2b) . Reticular disorder was observed in local areas of muscle fibers stained with NADH (as shown by Fig. 2c) . When muscle fibers stained with ATPase staining (as shown in Fig. 2d ), Part IIB atrophy of muscle fibers were observed, but no signs of necrosis, phagocytic changes, or regenerative fibers were observed. No infiltration of inflammatory cells was seen in the intermuscular septum. In accord with histopathological analysis, TEM revealed atrophic changes in scattered muscle fibers, Myofascial collapse, and basement membrane folding were also observed (Fig. 3) , which suggesting drug-induced myopathy rather than neurogenic damage.
Drug induced myopathy was highly suspicious, cyclosporine was withdrawn and replaced with cyclophosphamide tablets, prednisone remain unchanged and other symptomatic therapies were also administered. Four weeks later, bilateral thigh muscle atrophy showed improvement and lower limb weakness was obviously alleviated. Physical examination showed upper limb muscle strength of grade V, left lower limb muscle strength of grade IV, and right lower limb muscle strength of grade III. The patient could stand and walk with the help of others. He was discharged from the hospital and followed up regularly. Gradually, his thigh muscle atrophy was alleviated so that he was able to walk independently.
Discussion
Cyclosporine A-induced musculoskeletal diseases are rarely reported and CsA-induced muscle atrophy is even less common. To the best of our knowledge, this is the first report in medical literature of myopathy with subacute muscular atrophy associated with cyclosporine A. CsA-induced myopathy characterized by mitochondrial dysfunction is typically manifested as ragged red fibers, some COX-deficient fibers, disordered fibers stained with NADH and SDH, and intracellular lipid droplet aggregation. [2] The pathological findings from COX, NADH, and SDH staining of biopsied muscle resembled common drug-induced myopathy characterized by mitochondrial dysfunction.
Cyclosporine A is an inhibitor of calcineurin (CaN, or protein phosphatase-3) the only serine/threonine phosphatase known to be regulated by calcium and calmodulin. Calcineurin has 3 subunits, CaNa, CaNb, and CaNɣ, of which CaNa and CnAb are widely expressed in skeletal muscle. [3, 4] The activation of CaN may play an important role in the growth of skeletal muscle. Musaro et al found that IGF-1 mediates the growth of rhabdomy striated muscle cells by activating CaN and its downstream target NFAT transcription factor. [5] Recently, CaN was found to have distinct effects on muscle growth and muscle mass maintenance among different muscle phenotypes, and to differentially affect Medicine muscle growth regulation and muscle mass maintenance according to muscle type and growth cycle. Recent research has found that CaN can activate the expression of peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1a), [6] a transcriptional co-activator that promotes the transformation of type IIb muscle fibers into type I and type IIa muscle fibers by activating muscle creatine kinase (MCK). [7] Further, PGC-1a inhibits the ubiquitin-proteasome and autophagy-lysosome systems by suppressing forehead transcription factor O (FOXO) expression, thereby preventing www.md-journal.com muscular atrophy. [8] The expression of PGC-1a mRNA was significantly lower in the hind leg muscles of CaNaÀ/À and CaNbÀ/À mice compared to wild-type mice, and overexpression of CaN in skeletal muscle led to the overexpression of PGC-1a. These findings suggest that CaN signaling directly influences expression of PGC-1a [9] and that CaN inhibitors (such as CsA) may suppress PGC-1a expression and weaken the inhibitory effect on FOXO, leading to muscle atrophy. The IGF-1/PI3K/ AKT signaling pathway is also strongly implicated in skeletal muscle hypertrophy and muscle protein synthesis. [10] Some studies suggest that CaN inhibitors (such as CsA) can suppress the IGF-1/PI3K/AKT signaling pathway, dephosphorylate FOXO, and activate the ubiquitin-proteasome and autophagylysosome systems, thereby resulting in muscle atrophy. [7] In summary, CsA-induced myopathy with muscular atrophy is rare and serious, which can be identified according to pathological characteristics.
